reports
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 10, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,753,631 shares, corresponding to 4.85% of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.00% (previously...
- ABGSC Consumer Goods Research
- Alice Beer
- Benjamin Wahlstedt
- Fredrik Ivarsson
Boozt AB: 1 director
A director at Boozt AB sold after exercising options/sold 47,420 shares at 84.423SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed ...
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2). Please read the full announcement in PDF. Attachment
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
Combining EVP roles of Human Health Biosolutions and Strategy & Integr...
Combining EVP roles of Human Health Biosolutions and Strategy & Integration As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration. COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy & Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vi...
- ABGSC Consumer Goods Research
- Alice Beer
- Benjamin Wahlstedt
- Fredrik Ivarsson
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
- Geir Hiller Holom
PhotoCure (Buy, TP: NOK80.00) - Generally in line
Photocure reported c7% YOY product revenue growth for Q1, but operating expenses rose substantially, resulting in EBIT of NOK-5.6m, down YOY from NOK0.7m in Q1 2024. The company reiterated its guidance for 2025. A webcast is scheduled for today at 14:00 CET.
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Sten Gustafsson
Novonesis delivered a strong Q1 with 11% organic growth and confirms f...
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, say...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.